QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-neutral-on-avidity-biosciences-maintains-72-price-target

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Neutral and maintains $72 price target.

 avidity-biosciences-q3-eps-127-misses-111-estimate-sales-12475m-beat-1932m-estimate

Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of ...

 td-cowen-downgrades-avidity-biosciences-to-hold-lowers-price-target-to-74

TD Cowen analyst Ritu Baral downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and lowers the price target from $7...

 chardan-capital-downgrades-avidity-biosciences-to-neutral-lowers-price-target-to-72

Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price targ...

 novartis-maintains-outlook-even-as-generics-bite-into-profits

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighe...

 rbc-capital-downgrades-avidity-biosciences-to-sector-perform-raises-price-target-to-72

RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the p...

 merger-monday-makes-comeback-as-us-ma-tops-80-billion-in-24-hours

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acqui...

 avidity-biosciences-soars-after-72-per-share-novartis-takeover

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

 citigroup-downgrades-avidity-biosciences-to-neutral-lowers-price-target-to-72

Citigroup analyst Geoff Meacham downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target ...

 raymond-james-downgrades-avidity-biosciences-to-market-perform

Raymond James analyst Martin Auster downgrades Avidity Biosciences (NASDAQ:RNA) from Strong Buy to Market Perform.

 bernstein-downgrades-avidity-biosciences-to-market-perform-raises-price-target-to-72

Bernstein analyst William Pickering downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Market Perform and raises...

 needham-downgrades-avidity-biosciences-to-hold-maintains-price-target-to-65

Needham analyst Joseph Stringer downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and maintains the price target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION